The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...
Everyday Health on MSN
How to manage a career and family during an ulcerative colitis treatment switch
Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics ...
New ECCO dietary therapy guidelines for IBD clarify the role of enteral nutrition, Mediterranean diet, supplements, and RD ...
Aminosalicylate (5-ASA) therapy is often the first treatment option for patients presenting with mild to moderate ulcerative colitis (UC). Symptom improvements can be observed within 2 to 4 weeks ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...
Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...
Everyday Health on MSN
The 'prior auth' playbook for ulcerative colitis: cutting through the red tape
Don't let insurance delays stall your ulcerative colitis remission. Learn how to navigate prior authorization, step therapy, and specialty pharmacy hurdles.
Nearly 70% of adolescents and young adults stop taking oral 5-aminosalicylic acid (5-ASA) maintenance therapy within 12 months of ulcerative colitis (UC) diagnosis, new research from the United ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results